stocktools
Offerings // Liminatus Pharma, Inc.

LIMN offering history

Every offering-related filing in Liminatus Pharma, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 109 filings back to May 2, 2023.

Last executed offering
Nov 3, 2026
8-K — priced deal (shares or notes)
Last registration (announced)
Jun 24, 2026
S-1 — capacity, not a sale
Executed, last 12 months
5
424B pricings + 8-K 3.02 sales
Registered, last 12 months
2
S-1/S-3/F-series registrations
DateFilingWhat it means
Nov 3, 20268-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Jul 6, 20268-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Jun 24, 2026S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
Jun 3, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Jun 3, 20268-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Feb 18, 2026424B4 →EXECUTEDFinal prospectus — offering priced (typical for IPOs and marketed share deals)
Feb 13, 2026EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Feb 11, 2026S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
Feb 9, 20268-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Aug 13, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Aug 12, 2025EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Jul 28, 2025S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
Jul 17, 20258-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Jun 24, 2025S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
May 6, 20258-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Feb 7, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Feb 6, 2025EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Aug 12, 2024424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Aug 9, 2024EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
LIMN offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes — EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full LIMN workspace →
LIMN offering FAQ

When did LIMN last execute an offering?

Per SEC filings, Liminatus Pharma, Inc.'s most recent priced offering document is a 8-K filed 2026-11-03. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did LIMN last announce or register an offering?

The most recent registration is a S-1 filed 2026-06-24. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.

Free to use. No account, no card.